Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2020

View Archived Issues

New search method, new antibiotic MOA

JAK inhibitors build bone, no inflammation necessary

FDA approves IND application for phase IIb study of CMN-001 in advanced RCC

Passengers, noncoding genome affect how cancers play out

Mesoblast reports clinically meaningful outcomes for remestemcel-L in chronic GVHD

Enrollment ongoing in phase I/II study of MB-102

Novartis initiates first-in-human trial of WVT-078 in multiple myeloma

VBL initiates phase II study of VB-111 and nivolumab in metastatic colorectal cancer

Results from ongoing phase I study of ciforadenant with or without atezolizumab in mCRPC

BT-200 blocks VWF and platelet function in whole blood of patients with acute stroke

AT-845 shows safety and robust efficacy in preclinical models

New CDK8/19 inhibitors described by Biocad CJSC

Bristol-Myers Squibb discovers toll-like receptor 7 agonists

Sumitomo Dainippon Pharma describes anticancer chromen derivatives

Artios Pharma patents DNA polymerase eta inhibitors

Antabio SAS discovers serine beta-lactamase inhibitors

Oncofid-P-b shows promise in bladder cancer patients unresponsive to BCG

Chloroquine phosphate improves COVID-19-associated pneumonia in patients

EncuraGen presents new ADIPOR1 agonist BHD-1028 for type 2 diabetes, obesity and NASH

Phase IIb/III study of oral masitinib in PPMS and nSPMS meets primary endpoint

FDA approves Anjeso for moderate to severe pain

New phase I/IIa trial studies IHA infusion of TG-6002 for liver metastases from colorectal cancer

Agenus reports new data from cancer immunotherapy programs

Opdivo approved in Japan for advanced esophageal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...